Newburyport (MA, USA) – AdvancedDx Biological Laboratories USA Inc., a subsidiary of ABL Diagnostics (FR001400AHX6 – ABLD), a publicly listed company on Euronext that specializes in developing molecular biology assays and software for microbiology laboratories, has announced a new distribution agreement with Medline Industries, LP (www.medline.com).
Under the agreement, Medline will have the non-exclusive rights to promote and sell ABLD’s Next Generation Sequencing (NGS) solutions in the United States, including their new high throughput library preparation kits. The NGS market is projected to reach USD 1.42 billion in 2022 and is expected to have a compound annual growth rate of 13.16% from 2023 to 2030. ABLD’s NGS kits aim to streamline the process of preparing and pooling libraries for a wide range of samples and species.
“We are thrilled to begin distributing ABL Diagnostics’ NGS kits in the U.S.,” said Nicole Krpan, General Manager of Medline Laboratories Division. “This partnership will allow us to expand our portfolio and offer more efficient solutions to laboratories and genomic centers involved in NGS sequencing.”
The NGS kits are designed to increase efficiency and decrease workflow time, with a turnaround time of approximately 75 minutes for the entire library preparation process. They also boast high-quality DNA libraries with high yields and dual indexing capabilities, making them compatible with all Illumina NGS systems. “Our NGS Kits help eliminate bottlenecks related to cost, time, and labor, making them one of the most cost-effective high-throughput library preparation solutions on the market,” said Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics.
The terms of the agreement have not been disclosed.
ABOUT ADVANCEDDX BIOLOGICAL LABORATORIES USA INC & ABL DIAGNOSTICS
AdvancedDx Biological Laboratories USA Inc. is a subsidiary of ABL Diagnostics S.A. (ABLD), a worldwide leader in molecular biology assays and genotyping through DNA sequencing with their DeepChek® technology. ABL Diagnostics, based in Woippy, is a publicly listed company on Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6). Their products generate recurring revenues and cover one of the largest portfolios of microbiology applications.
ABL Diagnostics sells their products globally through their sales team and an exclusive network of distributors on all continents. Their clients include academic and private laboratories, as well as researchers looking to implement innovative and robust microbiology solutions. It is the responsibility of individuals to inquire about the registration status of ABL’s products in their region in order to comply with local regulations. Only Research Use Only (RUO) tests are available for sale in the USA, as listed on the FDA website. For further information, please visit www.abldiagnostics.com.
ABOUT MEDLINE INDUSTRIES, LP
Medline is a healthcare company that specializes in manufacturing, distributing, and providing solutions to improve the overall performance of healthcare. They partner with providers across the continuum of care to activate clinical and supply chain resources for the best possible patient care. With the ability to solve problems quickly and the scale to partner with providers for sustained success, Medline invests in their customers’ future and rapidly responds to changing market needs with customized solutions. Headquartered in Northfield, Illinois, Medline has over 38,000 employees worldwide and operates in more than 110 countries and territories. Learn more at www.medline.com.
CONTACTS
ABL Diagnostics
Chalom Sayada
General Manager
Tel.: +33 7 83 64 68 50
info@abldiagnostics.com
Medline Industries, LP
Carroll Henning
Public Relations Manager
Tel: 847-226-0587
chenning@medline.com
FORWARD LOOKING STATEMENT
This press release contains certain implicitly or explicitly forward-looking statements concerning ABL Diagnostics and its business. These statements are based on assumptions that ABL Diagnostics considers to be reasonable, but there can be no assurance that they will be verified. These statements are subject to numerous risks, including those set forth in the “Risk Factors” section of the universal registration document filed with the AMF on July 12, 2022 under number 22-296, available on the ABL Diagnostics website (www.abldiagnostics.com) and economic conditions, financial markets, and the markets in which ABL Diagnostics operates. The forward-looking statements contained in this press release are also subject to risks that are not currently known to ABL Diagnostics or are not currently considered material by ABL Diagnostics. The occurrence of any of these risks could cause actual results, financial conditions, performance, or achievements of ABL Diagnostics to be materially different from the forward-looking statements.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.